SEC Form 4 · accession 0001171843-15-002475
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Evan A. Stein
Director
Period of report
Apr 30, 2015
Accepted (ET)
May 4, 2015 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Apr 30, 2015 | J | 1,038,964 | $0.00 | D | 0 | I | See Footnote |
| Common SharesF4 | Apr 30, 2015 | J | 909,619 | $0.00 | A | 910,586 | I | See Footnote |
| Common SharesF6 | Apr 30, 2015 | J | 4,172 | $0.00 | A | 4,172 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1In kind pro-rata distribution from Lipoterx, Ltd. to its partners, without consideration.
- F2These shares were held by Lipoterx, Ltd. Lipoterx Holdings, LLC ("Lipoterx Holdings"), the general partner of Lipoterx, Ltd., had sole voting and investment power with respect to the shares held by Lipoterx, Ltd. The Reporting Person, the managing partner of Lipoterx Holdings, had sole voting and investment power with respect to the shares held by Lipoterx, Ltd.
- F3Acquisition by the Stein Family LLC, pursuant to an in kind pro-rata distribution by Lipoterx, Ltd. to its partners, without consideration.
- F4These shares are held by the Stein Family LLC, for which the Reporting Person serves as the managing member.
- F5Acquisition by Lipoterx Holdings, pursuant to an in kind pro-rata distribution by Lipoterx, Ltd. to its partners, without consideration.
- F6These shares are held by Lipoterx Holdings. The Reporting Person, the managing partner of Lipoterx Holdings has sole voting and investment power with respect to the shares held.